证券代码：002513 证券简称：蓝丰生化 公告编号：2023-105 特别提示： 1、本次拟回购注销的限制性股票数量为 2,653,000 股，回购价格为授予价 格 3.00 元/股加上银行同期存款利息。 2、回购注销完成后，公司总股本将由 373,936,278 股调整为 361,107,278 股。 3、上述回购注销事项尚需提交公司股东大会审议。 江苏蓝丰生物化工股份有限公司（以下简称"公司"）于 2023 年 11 月 13 日召开第七届董事会第七次会议、第七届监事会第五次会议，审议通过了《关于 2021 年限制性股票激励计划回购注销部分限制性股票的议案》，董事会同意回 购注销 34 名被激励对象已获授但尚未解除限售的 2,653,000 股限制性股票。现 将相关情况公告如下： 一、2021 年限制性股票激励计划已履行的相关审批程序 江苏蓝丰生物化工股份有限公司 关于 2021 年限制性股票激励计划回购注销部分限制性股票 的公告 本公司及董事会全体成员保证公告内容真实、准确和完整，不存在虚假记载、 误导性陈述或者重大遗漏。 1、2021 年 12 月 31 日，公司召开第六届董事会第八次会议，审议通过 ...

证券代码：002513 证券简称：蓝丰生化 公告编号：2023-104 江苏蓝丰生物化工股份有限公司 关于为控股子公司增加担保额度预计的公告 本公司及董事会全体成员保证公告内容真实、准确和完整，不存在虚假记载、 误导性陈述或者重大遗漏。 特别提示： 江苏蓝丰生物化工股份有限公司（以下简称"公司"）对外担保总额度超过 最近一期经审计净资产的 100%，本次担保对象安徽旭合新能源科技有限公司（以 下简称"旭合科技"）及其全资子公司云南旭合新能源技术有限公司（以下简称 "云南旭合"）资产负债率均超过 70%，请投资者注意担保风险。 一、担保情况概述 （一）已审批通过的担保额度情况 公司于 2023 年 9 月 22 日召开第七届董事会第三次会议、第七届监事会第三 次会议及 2023 年 10 月 10 日召开 2023 年第二次临时股东大会审议通过了《关于 对安徽旭合新能源科技有限公司提供担保额度预计的议案》，同意公司在旭合科 技 51%股权交割至公司名下后，为其提供总额不超过 3 亿元的担保，有效期为 2023 年第二次临时股东大会审议通过之日起至下一年度相应担保额度的股东大 会决议通过之日止。具体内容详见 20 ...

证券代码：002513 证券简称：蓝丰生化 公告编号：2023-102 江苏蓝丰生物化工股份有限公司 第七届董事会第七次会议决议公告 本公司及董事会全体成员保证公告内容真实、准确和完整，不存在虚假记载、 误导性陈述或者重大遗漏。 一、董事会会议召开情况 江苏蓝丰生物化工股份有限公司（以下简称"公司"）第七届董事会第七次 会议于 2023 年 11 月 13 日以通讯方式召开。本次会议已于 2023 年 11 月 10 日 以微信、电子邮件的方式通知全体董事。本次会议由公司董事长郑旭先生主持， 会议应出席董事 8 人，实际出席董事 8 人，监事和高管列席会议。本次会议的召 集、召开及表决程序符合《公司法》和《公司章程》的规定，合法有效。 二、董事会会议审议情况 （一）审议通过《关于为控股子公司增加担保额度预计的议案》 经审议，董事会同意本次为控股子公司安徽旭合新能源科技有限公司（以下 简称"旭合科技"）及其全资子公司云南旭合新能源技术有限公司（以下简称"云 南旭合"）增加人民币 20 亿元的担保额度，其中旭合科技新增担保额度 17 亿 元，云南旭合新增担保额度 3 亿元。本次新增担保额度是为了进一步支持控股子 ...

深 圳 证 券 交 易 所 关于对江苏蓝丰生物化工股份有限公司的 监管函 公司及全体董事、监事、高级管理人员吸取教训，及时整改，杜 绝上述问题的再次发生。 同时，提醒你公司及全体董事、监事、高级管理人员严格遵 守《证券法》《公司法》等法律法规，以及本所《股票上市规则》 及相关规定，真实、准确、完整、及时、公平地履行信息披露义 务，杜绝此类事件发生。 公司部监管函〔2023〕第 168 号 江苏蓝丰生物化工股份有限公司董事会： 根据你公司 2023 年 8 月 29 日提交的《关于深圳证券交易所 问询函的回复》，你公司信息披露存在以下问题：2023 年 4 月 28 日，你公司决定部分生产部门自 4 月 30 日起放假，并计划五一 节后恢复生产。五一假期后，相关生产部门未能正常复工复产， 你公司未就该停产事项进行披露。5 月 30 日，你公司下发硫磺 制酸装置检修通知，计划对该生产装置进行全面检修，并于当日 披露《关于公司部分生产装置停车检修的公告》。 你公司相关生产装置实际停车日期为 2023 年 4 月 30 日，但 直至 5 月 30 日才披露停车检修公告，且公告中未准确披露停车 时间及原因，信息披露存在 ...

证券代码：002513 证券简称：蓝丰生化 公告编号：2023-101 江苏蓝丰生物化工股份有限公司 关于控股二级子公司对外投资的公告 本公司及董事会全体成员保证公告内容的真实、准确、完整，没有虚假记载、 误导性陈述或者重大遗漏。 一、对外投资概述 江苏蓝丰生物化工股份有限公司（以下简称"公司"）控股二级子公司安徽 旭合清洁能源科技有限公司（以下简称"旭合清能"）拟以其自有资金对外投资 设立三级子公司安徽旭耀新能源科技有限公司（暂定名，以下简称"安徽旭耀"）、 朝阳旭合新能源科技有限公司（暂定名，以下简称"朝阳旭合"），并在安徽旭 耀下设四级子公司白城旭耀新能源科技有限公司（暂定名，以下简称"白城旭耀"）， 注册资本分别为人民币 500 万元、人民币 100 万元和人民币 1000 万元。 1 依法经营法律法规非禁止或限制的项目）许可项目：发电业务、输电业务、供（配） 电业务（依法须经批准的项目，经相关部门批准后方可开展经营活动，具体经营 项目以相关部门批准文件或许可证件为准） 股权结构：公司控股一级子公司安徽旭合新能源科技有限公司（以下简称"旭 合科技"）持有其 100%股权 本次投资事项已经公司第七届董事 ...

证券代码：002513 证券简称：蓝丰生化 公告编号：2023-099 江苏蓝丰生物化工股份有限公司 关于控股子公司年产 10GW 高效 N 型光伏电池及组件 项目（一期）部分投产的公告 本公司及董事会全体成员保证公告内容真实、准确和完整，不存在虚假记载、 误导性陈述或者重大遗漏。 一、项目概述 江苏蓝丰生物化工股份有限公司（以下简称"公司"）控股子公司安徽旭合 新能源科技有限公司（以下简称"旭合科技"）年产 10GW 高效 N 型光伏电池及 组件项目已于 2022 年 10 月通过政府相关部门备案并在安徽省滁州市苏滁现代 产业园投资建设。2023 年 11 月 6 日，该项目（一期）5GW 高效 N 型电池及组件 生产线中部分生产线已建设完成并逐步投入生产。 二、对公司的影响 本次年产 10GW 高效 N 型光伏电池及组件项目（一期）部分投产，将进一步 加速公司新能源业务板块的发展，符合公司转型升级的发展战略。本项目建成投 产将为公司创造新的业绩增长点，有利于提升公司整体效益，增强公司综合竞争 力，符合全体股东的利益。 三、风险提示 该项目从投产到规模量产尚需一定时间，后续可能存在因市场环境变化、竞 争加剧 ...

证券代码：002513 证券简称：蓝丰生化 公告编号：2023-100 江苏蓝丰生物化工股份有限公司 第七届董事会第六次会议决议公告 本公司及董事会全体成员保证公告内容真实、准确和完整，不存在虚假记载、 误导性陈述或者重大遗漏。 一、董事会会议召开情况 江苏蓝丰生物化工股份有限公司（以下简称"公司"）第七届董事会第六次 会议于 2023 年 11 月 6 日以通讯表决方式召开。本次会议通知已于 2023 年 11 月 3 日以微信、电子邮件的方式通知全体董事。本次会议由公司董事长郑旭先生主 持，应出席董事 8 人，实际出席董事 8 人，监事和高管列席会议。本次会议的召 集、召开及表决程序符合《公司法》和《公司章程》的规定，合法有效。 二、董事会会议审议情况 （一）审议通过《关于控股二级子公司对外投资的议案》 2 公司控股二级子公司安徽旭合清洁能源科技有限公司拟以其自有资金对外 投资设立三级子公司安徽旭耀新能源科技有限公司（暂定名，以下简称"安徽旭 耀"以市场监督管理局最终核准为准）、朝阳旭合新能源科技有限公司（暂定名， 以市场监督管理局最终核准为准），并在安徽旭耀下设四级子公司白城旭耀新能 源科技有限公司（暂 ...

Financial Performance - Revenue for Q3 2022 was ¥267,445,171.54, a decrease of 39.95% compared to the same period last year[4] - Net profit attributable to shareholders was -¥10,553,027.29, a decline of 63.26% year-on-year[4] - The net profit attributable to shareholders after deducting non-recurring gains and losses was -¥12,176,122.79, down 59.10% from the previous year[4] - Basic and diluted earnings per share were both -¥0.0282, a decrease of 64.72% compared to the same period last year[4] - The net profit attributable to the parent company was a loss of CNY 12,096,001.39, an improvement compared to a loss of CNY 42,229,317.91 in the previous period[19] - Basic and diluted earnings per share were both reported at -0.0323, an improvement from -0.1242 in the previous period[19] Assets and Liabilities - Total assets at the end of the reporting period were ¥1,611,177,295.20, a decrease of 6.76% from the end of the previous year[4] - As of September 30, 2022, total current assets amounted to CNY 397,463,271.52, a decrease from CNY 546,039,989.40 at the beginning of the year, representing a decline of approximately 27.2%[14] - Total non-current assets reached CNY 1,213,714,023.68, an increase from CNY 1,181,909,973.11 at the start of the year, indicating a growth of about 2.7%[15] - The total assets of the company were CNY 1,611,177,295.20, down from CNY 1,727,949,962.51, reflecting a decrease of approximately 6.7%[15] - Total current liabilities were CNY 931,775,922.03, a reduction from CNY 1,045,237,076.35, showing a decline of around 10.9%[15] - The company's total liabilities amounted to CNY 943,063,196.72, down from CNY 1,061,312,988.31, representing a decrease of about 11.1%[15] - The company’s total equity attributable to shareholders reached CNY 668,114,098.48, slightly up from CNY 666,636,974.20[18] Cash Flow - Cash flow from operating activities showed a net outflow of -¥41,132,208.79, a significant decline of 171.07%[4] - Cash flow from operating activities showed a net outflow of CNY 41,132,208.79, contrasting with a net inflow of CNY 57,873,864.42 in the previous period[19] - The net cash flow from investment activities was 11,796,141.15, a significant improvement compared to -92,691,397.23 in the previous period[20] - Total cash inflow from financing activities reached 199,790,100.00, up from 136,000,000.00 in the prior period[20] - The net cash flow from financing activities was 5,929,296.41, contrasting with -96,660,240.95 in the previous period[20] - The cash and cash equivalents at the end of the period totaled 11,693,152.81, down from 95,348,563.04 at the end of the previous period[20] - The company experienced a net decrease in cash and cash equivalents of 21,273,873.63 during the quarter[20] - The total cash outflow from investment activities was 54,218,722.08, compared to 92,669,182.62 in the previous period[20] - The company received 101,550,000.00 in cash from investment absorption during the quarter[20] - The cash paid for debt repayment was 82,000,000.00, a decrease from 122,041,192.54 in the previous period[20] - The impact of exchange rate changes on cash and cash equivalents was 2,132,897.60, compared to 31,368.60 in the previous period[20] Shareholder Information - The top ten shareholders collectively hold 58.56% of the company's shares, with Jiangsu Suhua Group Co., Ltd. being the largest shareholder at 9.18%[12] - The company has no preferred shareholders as of the reporting period[13] Operational Activities - The company reported a 375.96% increase in other non-current assets, totaling ¥94,020,881.37 due to reclassification of long-term assets[9] - Research and development expenses decreased by 71.50% to ¥3,138,082.33 compared to the same period last year[10] - The company received government subsidies amounting to ¥3,210,265.53, an increase of 146.61% year-on-year[10] - The company reported a significant increase in cash received from the disposal of fixed assets, amounting to ¥6,014,863.23, a rise of 27176.16%[10] - Total operating revenue for the period reached CNY 1,091,224,761.19, a slight increase from CNY 1,085,671,226.21 in the previous period, representing a growth of approximately 0.5%[17] - Total operating costs decreased to CNY 1,120,927,109.52 from CNY 1,143,331,222.90, marking a reduction of about 2.0%[17] - Research and development expenses significantly decreased to CNY 3,138,082.33 from CNY 11,010,052.54, a reduction of approximately 71.5%[17] - Sales expenses were reduced to CNY 7,901,158.93 from CNY 24,103,059.75, indicating a decrease of about 67.2%[17] - The company reported a significant increase in other income to CNY 3,210,265.53 from CNY 1,301,750.00, representing a growth of approximately 146.4%[17] Audit Information - The third quarter report was not audited[21]

Financial Performance - The company's revenue for Q3 2023 was ¥236,491,965.97, a decrease of 11.57% compared to the same period last year[4] - Total revenue for Q3 2023 was CNY 763,015,745.63, a decrease of 30.0% compared to CNY 1,091,224,761.19 in the same period last year[21] - The net profit attributable to shareholders was -¥44,314,002.86, representing a decline of 319.92% year-on-year[4] - Operating profit for Q3 2023 was CNY -131,629,535.52, compared to CNY -18,894,383.69 in Q3 2022, indicating a significant decline in profitability[21] - The net loss for the third quarter was CNY 135.98 million, compared to a net loss of CNY 12.10 million in the previous year, indicating a significant increase in losses[22] - The total comprehensive loss for the quarter was CNY 135.70 million, compared to a loss of CNY 12.10 million in the previous year[22] Earnings and Shareholder Information - The basic earnings per share for the period was -¥0.1186, down 320.70% from the previous year[4] - The basic and diluted earnings per share for the third quarter were both CNY -0.3638, compared to CNY -0.0323 in the previous year[22] - The total number of ordinary shareholders at the end of the reporting period was 16,909, with no preferred shareholders[13] - The top ten shareholders hold a combined 70.32% of the company's shares, with the largest shareholder, Zheng Xu, holding 18.04%[13] Assets and Liabilities - Total assets at the end of the reporting period were ¥1,460,768,263.53, a decrease of 1.00% from the end of the previous year[4] - Non-current assets decreased to CNY 1,061,735,281.47 from CNY 1,115,270,289.88, a decline of 4.8%[18] - Total current liabilities increased to CNY 1,150,600,333.84, up 10.9% from CNY 1,036,911,460.90[19] - The company’s total equity attributable to shareholders decreased by 37.59% to ¥223,186,388.39 compared to the previous year[4] Cash Flow - The company's cash flow from operating activities showed a net outflow of -¥114,734,899.63, a decline of 178.94% year-to-date[4] - The cash flow from operating activities showed a net outflow of CNY 114.73 million, worsening from a net outflow of CNY 41.13 million in the same period last year[23] - The cash flow from financing activities generated a net inflow of CNY 170.55 million, a substantial increase from CNY 5.93 million in the same period last year[24] - The company’s cash and cash equivalents were impacted by exchange rate fluctuations, resulting in a decrease of 88.60% in the cash effect from foreign exchange[11] Research and Development - Research and development expenses increased by 106.74% to ¥6,487,821.43, indicating a focus on innovation[10] - Research and development expenses increased to CNY 6,487,821.43, up 106.0% from CNY 3,138,082.33 year-on-year[21] Other Income and Expenses - The company reported a significant increase in other income by 46.27% to ¥4,695,645.56, primarily due to tax exemptions[10] - The company incurred operating expenses of CNY 535.75 million, a decrease from CNY 1,076.80 million in the same period last year[23] - The company received CNY 8.33 million in tax refunds during the quarter, down from CNY 43.52 million in the same period last year[23] Share Transactions and Acquisitions - The company completed the transfer of 33,610,000 shares from a major shareholder, representing 8.99% of the total share capital, to Hainan Wenqin Private Fund Management[15] - The company acquired 51% of Anhui Xuhe New Energy Technology Co., Ltd. for RMB 67,523,490, becoming its controlling shareholder[16] - The company is actively expanding its market presence through strategic acquisitions and investments in new technologies[16] Stock Structure - The company’s stock structure changed post-acquisition, with Bluefeng holding 51%, Zheng Xu 31.85%, and other investors holding the remainder[16]

证券代码：002513 证券简称：蓝丰生化 公告编号：2023-097 具体详见 2023 年 10 月 31 日刊登在公司指定信息披露网站巨潮资讯网 （www.cninfo.com.cn）及《上海证券报》、《证券时报》、《中国证券报》上的 相关公告。 本公司及监事会全体成员保证公告内容真实、准确和完整，不存在虚假记载、 误导性陈述或者重大遗漏。 一、监事会会议召开情况 江苏蓝丰生物化工股份有限公司（以下简称"公司"）第七届监事会第四次 会议于 2023 年 10 月 30 日以通讯表决方式召开。本次会议通知已于 2023 年 10 月 27 日以微信、电子邮件的方式通知全体监事。本次会议由公司监事会主席韩 宜辰先生主持，应出席监事 3 人，实际出席监事 3 人。本次会议的召集、召开及 表决程序符合《公司法》和《公司章程》的规定，合法有效。 二、监事会会议审议情况 （一）审议通过《关于公司 2023 年第三季度报告的议案》 江苏蓝丰生物化工股份有限公司 经审核，监事会认为公司《2023 年第三季度报告》的编制程序符合法律、行 政法规的规定，报告内容真实、准确、完整地反映了公司的实际情况，不存在任 何虚假记载、 ...